MNOV
Medicinova Inc
Halal Rating :
Last Price
$1.88
Last updated:
Market Cap
-
7D Change
-5.53%
1 Year Change
25.33%
Company Overview
Industries
Exchange
Next Earnings Date
MediciNova, Inc. is a biopharmaceutical company focused on developing novel therapeutics for the treatment of diseases with unmet medical needs. Their primary drug candidates include MN-166 (ibudilast) for neurological conditions and MN-001 (tipelukast) for fibrotic diseases. The company is currently in various stages of clinical trials for treating progressive multiple sclerosis, ALS, substance dependence, and other conditions.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Medicinova Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.